HoldsUp

Ronald Krauss

Children’s Hospital Oakland Research Institute

Ronald Krauss, M.D., is the director of atherosclerosis research at Children’s Hospital Oakland Research Institute and an adjunct professor at UCSF and UC Berkeley. His research focuses on lipid metabolism, having developed an assay to quantify low-density lipoprotein (LDL) particle size and concentration. His published work covers dietary effects on cardiometabolic disease and insulin sensitivity, statin responses, and the relationship between cholesterol regulation, genetics, and Alzheimer's disease.

38 claims checked on air: 2 context 2 overstated 33 supported 1 unverified 2 flagged

What they said on air - supported

2 citing their own research

0:02:33supportedmoderateDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

People with heart disease or higher heart disease risk tend to have a higher proportion of smaller, denser LDL particles, whereas healthier individuals have more large, buoyant LDL particles.

"people with a higher heart disease risk and people who have evidence of heart disease tend to have more of the particles that are the smaller and more dense particles. And those individuals that are more healthy tended to have more of the larger, more buoyant LDL." (said at 0:02:33)

A large body of observational cohort studies and meta-analyses demonstrates that individuals with coronary heart disease or elevated cardiovascular risk have a higher proportion and concentration of small, dense low-density lipoprotein (sdLDL) particles (often termed atherogenic lipoprotein phenotype or pattern B), whereas healthier individuals without dyslipidemia typically exhibit a predominance of larger, more buoyant LDL particles (pattern A). A systematic review and meta-analysis of 21 prospective studies encompassing 30,628 participants confirmed that higher sdLDL levels are significantly associated with an increased risk of incident coronary heart disease (RR 1.36, 95% CI: 1.21–1.52).

0:03:35supportedmoderateDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Smaller, dense LDL particles have a greater tendency to enter the arterial wall, bind more tightly to artery tissue, and oxidize more rapidly compared to large LDL particles.

"even though these smaller particles carry less cholesterol, they do have a greater tendency to wind up in the artery wall. They can be bound more tightly to artery tissue, and once they get into the arteries, they tend to stick and they tend to be oxidized more rapidly." (said at 0:03:35)

The claim accurately describes the established biochemical mechanisms of small, dense low-density lipoprotein (sdLDL) particles. Published reviews and experimental literature confirm that small, dense LDL particles have a greater propensity for transport into the subendothelial space, exhibit higher binding affinity for arterial wall proteoglycans, and demonstrate increased susceptibility to oxidative modification compared to larger LDL particles. Certainty is graded as moderate because these mechanisms are supported primarily by in vitro, ex vivo, and physiological tracer studies rather than direct clinical trial evidence.

0:05:44supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Virtually all human tissues under normal physiological conditions are capable of manufacturing their own cholesterol.

"most tissues, in fact really virtually all tissues in the human body under normal conditions, are capable of manufacturing their own cholesterol." (said at 0:05:44)

In human physiology, virtually all tissues and nucleated cells express the enzymatic machinery necessary for de novo cholesterol biosynthesis (such as HMG-CoA reductase and DHCR24) from acetyl-CoA under normal physiological conditions. Mature red blood cells lack internal organelles and cannot synthesize cholesterol, but all major organ tissues maintain active endogenous cholesterol biosynthetic and regulatory pathways.

0:08:12supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Lipase breaks down triglycerides in VLDL particles, causing them to shrink and lose triglyceride while retaining most cholesterol, converting them into small, dense LDL particles.

"As that process occurs through a lipase that breaks down the triglyceride, the particles get smaller and smaller. They lose their triglyceride, but they tend to retain most of their cholesterol. So there is a shrinkage from what is a big, buoyant, triglyceride-rich VLDL particle to a smaller, more dense LDL particle." (said at 0:08:12)

The speaker accurately describes the classical delipidation cascade of triglyceride-rich lipoproteins. Lipases, primarily lipoprotein lipase (LPL) and hepatic lipase (HL), hydrolyze core triglycerides within large, buoyant very low-density lipoprotein (VLDL) particles. As the core triglyceride content is depleted while cholesteryl esters are predominantly retained, the particle undergoes progressive shrinkage and remodelling into intermediate-density lipoprotein (IDL) and ultimately smaller, denser low-density lipoprotein (LDL) particles.

0:09:13supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

The adrenal glands and gonads utilize cholesterol delivered by LDL to synthesize steroid hormones.

"And LDL are used by tissues: adrenal gland uses LDL cholesterol, the gonads use cholesterol to synthesize, for example, hormones that are made by those tissues." (said at 0:09:13)

Steroidogenic tissues, primarily the adrenal cortex and the gonads (ovaries and testes), use cholesterol as the essential precursor for synthesizing steroid hormones (including cortisol, aldosterone, androgens, and estrogens). While these tissues can synthesize cholesterol de novo or mobilize it from intracellular lipid droplets, they rely heavily on receptor-mediated uptake of circulating plasma lipoproteins, including low-density lipoprotein (LDL) via LDL receptor endocytosis and high-density lipoprotein (HDL) via SR-BI.

0:11:11supportedmoderateDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Low HDL cholesterol is a stronger overall statistical predictor of heart disease risk than high LDL cholesterol.

"In fact, HDL cholesterol—low HDL cholesterol is a stronger predictor of heart disease risk overall than is high LDL cholesterol." (said at 0:11:11)

Observational epidemiological data, most notably from the classic Framingham Heart Study and the Cooperative Lipoprotein Phenotyping Study, demonstrate that high-density lipoprotein (HDL) cholesterol is a stronger independent statistical predictor of coronary heart disease (CHD) incidence and prevalence across broader age and demographic groups than low-density lipoprotein (LDL) cholesterol or total cholesterol. In landmark Framingham prospective analyses of men and women aged 49 to 82 years, low HDL cholesterol was the most potent lipid predictor (p < 0.001), while LDL cholesterol exhibited a statistically weaker association (p < 0.05). However, modern genetic (Mendelian randomization) and randomized trial evidence indicates that while low HDL is an exceptionally strong statistical marker/predictor of cardiovascular risk, raising HDL cholesterol does not causally reduce risk, unlike lowering LDL.

0:12:40supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Low HDL cholesterol levels are metabolically associated with increased levels of small, dense LDL particles.

"Because low HDL cholesterol is also associated with an increased level of these small LDL particles." (said at 0:12:40)

Low HDL cholesterol is a well-established component of the metabolic lipid profile known as atherogenic dyslipidemia (often associated with insulin resistance, metabolic syndrome, and obesity), which is classically characterized by elevated triglyceride levels, decreased HDL cholesterol, and an increased proportion of small, dense LDL (sdLDL) particles.

0:14:24supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Therapeutic interventions designed to raise HDL cholesterol have failed to reduce heart disease risk, whereas interventions lowering LDL have consistently succeeded.

"efforts to reduce heart disease risk by treatments that raise HDL cholesterol have failed, whereas almost every treatment that has been aimed at lowering LDL sufficiently has been successful." (said at 0:14:24)

Extensive randomized trial evidence and systematic reviews confirm that pharmacologically raising HDL cholesterol levels has failed to reduce cardiovascular events or mortality, whereas lowering LDL cholesterol consistently yields proportional reductions in coronary heart disease risk. A large meta-regression of 108 randomized trials involving 299,310 participants found that changes in HDL cholesterol explained less than 1% of the variation in cardiovascular outcomes once adjusted for changes in LDL cholesterol. Clinical trials targeting HDL elevation (such as niacin trials evaluated in Cochrane reviews and cholesteryl ester transfer protein [CETP] inhibitor trials) failed to show cardiovascular benefit beyond what is predicted by LDL lowering, whereas therapies that substantially reduce LDL cholesterol (e.g., statins) consistently reduce major vascular events.

0:15:27supportedhightheir own paperDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Genetic variants associated with high LDL are associated with increased heart disease risk, whereas genetic variants associated with HDL cholesterol levels are almost never associated with heart disease risk.

"genes associated with high LDL are associated with heart disease risk. That's a very important pathologic connection, because genes ultimately are the blueprint for our biology, and if the genes associated with high LDL are also associated with heart disease risk, it says that the LDL is really the causal agent. The genes associated with variation in HDL cholesterol have almost in every case not been associated with heart disease risk" (said at 0:15:27)

Extensive Mendelian randomization studies and human genetic analyses demonstrate that genetic variants associated with higher LDL cholesterol are consistently and causally associated with increased risk of coronary heart disease and myocardial infarction. In contrast, genetic variants that specifically raise or lower plasma HDL cholesterol (such as variants in LIPG or multi-SNP genetic risk scores specific to HDL-C) show no significant causal association with myocardial infarction risk, despite the inverse association observed in observational epidemiology.

0:19:32supportedmoderateDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Apolipoprotein B (apoB) is an ancient protein whose lineage traces back evolutionarily to lobsters.

"Apolipoprotein B is a very big protein that is biologically ancient. It goes back to lobsters, and it's a very important and complicated protein that gives the integrity to the lipoprotein particle." (said at 0:19:32)

Apolipoprotein B (apoB) is an ancient, large structural scaffold protein belonging to the evolutionary superfamily of large lipid transfer proteins (LLTPs). Comparative genomics and biochemical studies demonstrate that apoB-like proteins and homologous lipid-transport proteins are conserved across ancient invertebrate lineages, including decapod crustaceans (such as lobsters, crabs, and shrimp), where they function in lipid packaging, transport, and lipoprotein integrity.

0:20:03supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Apolipoprotein B (apoB) is constitutively synthesized by the liver under tonic stimulation, and hepatic apoB secretion is primarily regulated through degradation rather than changes in its synthesis rate.

"Anyway, the apoB protein is constantly synthesized by the liver. It's under a tonic stimulation, so it's not much regulated. It's just continually being produced and degraded, which seems like a very inefficient process." (said at 0:20:03)

The speaker's statement accurately describes the established biology of apolipoprotein B (apoB) production in the liver. ApoB is constitutively transcribed and translated at a relatively constant rate with minimal transcriptional regulation. The secretion rate of apoB-containing lipoproteins is primarily controlled post-translationally by intracellular degradation (via proteasomal and non-proteasomal pathways in the endoplasmic reticulum and Golgi) depending on lipid availability and the activity of microsomal triglyceride transfer protein (MTP).

0:23:20supportedvery lowDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Pro-inflammatory cytokines including TNF-alpha and interferon stimulate VLDL secretion by the liver within minutes.

"we showed in collaboration with people at UCSF that cytokines such as TNF-alpha in particular, but interferon as well, stimulate the production of VLDL secretion by the liver. And so, again, infectious agent, inflammatory signals, cytokines are produced, increasing lipid synthesis, reducing the degradation of apoB, allowing the rapid export of these VLDL particles—all of that occurs in minutes." (said at 0:23:20)

Preclinical animal and in vitro hepatocyte studies confirm that pro-inflammatory cytokines, including TNF-alpha and interferons, rapidly stimulate hepatic de novo lipogenesis and VLDL secretion as part of the acute phase response. In rodents, administration of TNF-alpha increases plasma VLDL levels and stimulates hepatic VLDL secretion within 60 to 90 minutes. Because the mechanistic evidence for rapid stimulation of VLDL secretion and lipid synthesis by these cytokines derives primarily from animal and cellular experimental models, the certainty of evidence is graded as very low.

0:25:15supportedvery lowDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Increasing LDL receptor activity and hepatic LDL clearance from the blood lowers circulating lipopolysaccharide (LPS) levels.

"it has been shown that if you increase LDL receptor activity and increase LDL uptake from the blood, you can lower LPS levels." (said at 0:25:15)

Preclinical and in vitro studies demonstrate that circulating lipopolysaccharide (LPS) binds to lipoprotein particles (including LDL) and is cleared from the blood by hepatocytes via low-density lipoprotein receptor (LDLR)-mediated endocytosis. In animal models and cultured human hepatocytes, increasing LDLR expression or activity (such as by inhibiting PCSK9) enhances hepatic LPS uptake and clearance from the circulation, whereas LDLR knockout or downregulation significantly impairs LPS clearance. Because evidence establishing this specific clearance mechanism is derived from animal and cell-culture studies, the certainty is rated as very low.

0:25:43supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

All classes of plasma lipoproteins are capable of binding bacterial lipopolysaccharide (endotoxin).

"HDL does that to some extent, as well as mentioned. All lipoproteins are capable of binding LPS." (said at 0:25:43)

Published literature confirms that all major classes of plasma lipoproteins—including high-density lipoproteins (HDL), low-density lipoproteins (LDL), very-low-density lipoproteins (VLDL), and chylomicrons—are capable of binding and sequestering bacterial lipopolysaccharide (LPS, also known as endotoxin). Lipoproteins act as an arm of the innate immune system by sequestering pathogen-associated lipids, neutralizing their toxicity, and facilitating their clearance (chiefly mediated by HDL, but also involving LDL, VLDL, and postprandial chylomicrons).

0:26:44supportedmoderateDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

As LDL particles shrink in size, the apoB receptor recognition site becomes obscured, giving smaller LDL particles lower binding affinity for the LDL receptor.

"the smaller particles—in fact, this is an important feature of these small particles that I didn't mention earlier that may actually be one of the more important reasons that they're associated with heart disease risk—is they have less affinity for the LDL receptor. That's been shown by us and by others, that as the particle shrinks to a smaller size, the region of the particle that is recognized by the LDL receptor, which is actually a region of the apoB protein that is the receptor recognition site for the whole particle, gets to be obscured." (said at 0:26:44)

Biochemical and cellular studies confirm that small, dense low-density lipoprotein (LDL) particles exhibit conformational changes in apolipoprotein B-100 (apoB-100), including reduced epitope accessibility near the LDL receptor-binding region and altered critical lysine microenvironments. Consequently, small dense LDL particles display significantly lower binding affinity for the LDL receptor on human cells, leading to decreased receptor-mediated clearance and prolonged plasma residence time.

0:31:50supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

The US Dietary Guidelines removed the long-standing recommendation to limit dietary cholesterol intake to less than 300 mg per day due to a lack of supporting evidence.

"And then 15 years later, the current dietary guidelines come out saying, "Well, you know, after all these years of recommending keeping cholesterol less than 300 milligrams per day, we realize there's really no data to support that."" (said at 0:31:50)

The 2015–2020 Dietary Guidelines for Americans removed the previous recommendation limiting dietary cholesterol intake to less than 300 mg per day. The Dietary Guidelines Advisory Committee concluded that available evidence did not demonstrate an appreciable relationship between dietary cholesterol intake and serum cholesterol levels or cardiovascular disease risk.

0:33:58supportedhightheir own paperDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Saturated fat intake increases large LDL particles rather than small, dense LDL particles in the majority of the population.

"we've shown that the form of LDL that increases with saturated fat is not the small LDL, but the large LDL. And in fact, that led me to question whether or not saturated fat was really an important factor in heart disease risk, because our studies did not show that it was increasing small LDL in the majority of the population." (said at 0:33:58)

Randomized dietary intervention studies and comprehensive reviews confirm that in the general population, increasing dietary saturated fatty acid intake predominantly elevates concentrations of large, buoyant LDL particles rather than small, dense LDL particles. A landmark crossover feeding trial by Krauss and colleagues showed that saturated fat intake was positively correlated with the mass of large LDL particles and inversely correlated with small, dense LDL particles. A state-of-the-art review in the Journal of the American College of Cardiology similarly concluded that while saturated fatty acids raise total LDL cholesterol, in most individuals this rise is driven by larger LDL particles rather than small, dense LDL subclasses.

0:34:39supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Dr. Siri-Tarino and Dr. Ronald Krauss published a meta-analysis questioning the relationship between saturated fat intake and heart disease risk.

"we first published this with Dr. Siri-Tarino in my group about five years ago now, and we were really hit hard when we published that first paper questioning the relationship of saturated fat to heart disease risk." (said at 0:34:39)

Dr. Patty W. Siri-Tarino, Dr. Ronald M. Krauss, and colleagues published a landmark 2010 systematic review and meta-analysis of 21 prospective cohort studies (including 347,747 participants followed for 5 to 23 years). The meta-analysis concluded that intake of dietary saturated fat was not significantly associated with an increased risk of coronary heart disease, stroke, or cardiovascular disease, directly questioning the established direct association between saturated fat intake and cardiovascular disease risk.

0:35:23supportedlowDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Epidemiological evidence shows that red meat consumption, particularly processed red meat, is associated with adverse cardiovascular outcomes and decreased life expectancy.

"in fact, there is evidence from epidemiology that red meat, particularly processed red meat, which contains saturated fat, may have adverse effects on heart disease as well as life itself, life expectancy, and other diseases." (said at 0:35:23)

Large systematic reviews and meta-analyses of prospective cohort studies support the statement that red meat, and especially processed meat, is epidemiologically associated with increased risks of cardiovascular disease and all-cause mortality (reduced life expectancy). Because these findings are derived from observational cohorts subject to residual confounding, nutritional epidemiology frameworks (such as GRADE) typically grade the certainty of this evidence as low, though the direction of the observed association consistently aligns with the speaker's claim.

0:38:25supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Switching individuals from a baseline diet to a low-fat, high-carbohydrate diet converts larger LDL particles into smaller LDL particles.

"We had a completely contrary result: we found that people who started off with large LDL, when they were put on a low-fat diet, actually made their LDL smaller." (said at 0:38:25)

Controlled dietary crossover trials demonstrate that when individuals are shifted from a high-fat diet to an isocaloric low-fat, high-carbohydrate diet, there is a shift in LDL particle distribution from larger, buoyant LDL subfractions to smaller, denser LDL subfractions, including the conversion of a substantial proportion of individuals with predominantly large LDL (pattern A) to predominantly small LDL (pattern B).

0:38:55supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

High-carbohydrate diets promote hepatic VLDL particle production that leads to the atherogenic dyslipidemia phenotype: elevated triglycerides, increased small LDL, and lower HDL.

"High-carbohydrate diets can promote the production of these VLDL particles from the liver that make small LDL. So high carbohydrates clearly push lipoprotein metabolism in the direction of atherogenic dyslipidemia—all the features: high triglycerides, small LDL, and to some extent a lower HDL." (said at 0:38:55)

High-carbohydrate, low-fat diets stimulate hepatic de novo lipogenesis and very-low-density lipoprotein (VLDL) particle secretion, driving the classic atherogenic dyslipidemia triad: elevated plasma triglycerides, an increased proportion of small dense LDL particles (phenotype B), and reduced HDL cholesterol. Controlled dietary intervention trials and metabolic studies demonstrate that switching to a high-carbohydrate diet induces a shift from large, buoyant LDL to smaller, denser LDL subspecies alongside increased VLDL precursors and lower HDL levels.

0:40:08supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Table sugar and common added sugars consist of approximately 50% fructose and 50% glucose.

"fructose in particular among them, which is of course a component of table sugar and added sugars—half of that is fructose, the other half is glucose." (said at 0:40:08)

The chemical and nutritional composition of table sugar (sucrose) is a 1:1 disaccharide of glucose and fructose (50% fructose and 50% glucose). The most common added caloric sweeteners, such as sucrose and high-fructose corn syrup (HFCS-55 or HFCS-42), consist of approximately 50% fructose and 50% glucose.

0:42:07supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

When the liver metabolizes fructose, it stimulates de novo lipogenesis and fat production.

"I don't think there's any doubt that fructose makes fat. When the liver encounters fructose, it makes fat, and that starts this whole process in motion." (said at 0:42:07)

Hepatic metabolism of fructose directly stimulates de novo lipogenesis (DNL) and the synthesis of intrahepatic triglycerides. Unlike glucose metabolism, fructose uptake and initial phosphorylation in the liver bypass key regulatory metabolic checkpoints (such as phosphofructokinase), rapidly providing substrates (acetyl-CoA and glycerol-3-phosphate) and activating key lipogenic transcription factors (SREBP1c and ChREBP). Human isotope-tracer intervention studies and mechanistic reviews consistently demonstrate that fructose consumption increases hepatic DNL and promotes liver fat accumulation more potently than equicaloric amounts of other carbohydrates.

0:44:17supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

A study conducted by Harvard researchers failed to demonstrate a significant relationship between dietary glycemic index and LDL or other lipid levels.

"In fact, a study was just reported by a colleague of mine from Harvard in which they failed to show a relationship between glycemic index and LDL levels or lipid levels." (said at 0:44:17)

A randomized crossover-controlled feeding trial led by Harvard researchers (the OmniCarb trial, published in JAMA in 2014) evaluated 163 overweight adults across four controlled diets varying in carbohydrate amount and glycemic index in the context of a DASH-type diet. The trial found that lowering dietary glycemic index did not improve lipid profiles (including LDL or HDL cholesterol) or insulin sensitivity, concluding that selecting foods based on glycemic index did not improve cardiovascular risk factors.

0:48:18supportedmoderateDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Saturated fats consumed in fermented dairy products have been shown to provide metabolic benefits.

"and others have shown that when saturated fat is packaged in a dairy product, particularly a fermented dairy product, there may actually be some metabolic benefits." (said at 0:48:18)

Evidence from systematic reviews, observational cohort studies, and randomized trials demonstrates that the matrix of full-fat and fermented dairy products (such as cheese and yogurt) modulates the physiological impact of their saturated fat content. Consumption of fermented dairy foods has been associated with neutral or beneficial cardiometabolic outcomes, including neutral blood lipid responses, improved insulin sensitivity markers, and reduced risk of type 2 diabetes and cardiovascular disease compared to equivalent saturated fat from other dietary sources.

0:50:51supportedmoderateDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Small LDL particles are cleared less efficiently by LDL receptors than larger LDL particles.

"the role of the LDL receptor in clearing LDL particles and the fact that the small LDL particles are less uh efficiently removed by the LDL receptor" (said at 0:50:51)

Published biochemical and kinetic studies confirm that small, dense low-density lipoprotein (LDL) particles exhibit altered apolipoprotein B-100 conformation, leading to reduced binding affinity for the cellular LDL receptor. Consequently, small LDL particles are cleared more slowly from the circulation via receptor-mediated pathways compared to standard or intermediate-sized LDL particles, contributing to an extended plasma residence time.

0:51:48supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Statins lower LDL cholesterol predominantly by upregulating LDL receptor activity.

"and one accepts the well-established fact that a major mechanism by which statins lower LDL is by increasing LDL receptor activity" (said at 0:51:48)

The primary mechanism through which 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) lower circulating LDL cholesterol is well established. By inhibiting the rate-limiting step of intracellular cholesterol biosynthesis in hepatocytes, statins trigger sterol regulatory element-binding protein 2 (SREBP-2) activation, leading to the upregulation of cell-surface LDL receptors and increased clearance of LDL particles from the bloodstream.

0:52:13supportedmoderateDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Statins lower larger, cholesterol-rich LDL particles more efficiently than smaller, denser LDL particles.

"we've studied almost every statin um and shown that um the effects on smaller LDL particles, particularly the very smallest LDL particles, um are blunted compared with the larger LDL. It's not as if there's no effect at all, but they're they're less efficiently uh cleared. So statins tend to work primarily on the larger, cholesterol-rich LDL particles, and the lowering of LDL cholesterol by statins uh is more strongly related to that effect than the effect on the smaller LDL" (said at 0:52:13)

The speaker's statement accurately reflects kinetic and lipoprotein subfraction research demonstrating that statin-mediated LDL receptor upregulation preferentially increases the clearance of larger, buoyant LDL particles compared to smaller, denser LDL particles. Experimental kinetic models show that smaller LDL particles have a significantly lower fractional catabolic rate and reduced LDL-receptor affinity compared with larger LDL particles, meaning standard statin therapy reduces large, cholesterol-rich LDL subclasses to a greater relative extent than very small, dense LDL particles.

0:53:08supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Statin therapy reduces cardiovascular disease risk by approximately 30% to 40%.

"one of the most effective treatments we have for any medical condition, other than it maybe antibiotics for infections, uh are statins for lowering LDL—30, 40% reduction in risk." (said at 0:53:08)

Large-scale meta-analyses of randomized controlled trials confirm that statin therapy significantly reduces the relative risk of cardiovascular disease events by approximately 20% to 40%, depending on the degree of LDL cholesterol lowering and baseline risk. The Cholesterol Treatment Trialists' (CTT) Collaboration meta-analysis of 26 randomized trials (approx. 170,000 participants) demonstrated a 22% reduction in major vascular events per 1.0 mmol/L (~39 mg/dL) reduction in LDL cholesterol (rate ratio 0.78, 95% CI 0.76–0.80), with greater reductions (around 40% to 50%) observed with 2 to 3 mmol/L reductions in LDL cholesterol. Cochrane systematic reviews in primary prevention similarly demonstrate a 25% to 38% relative risk reduction across combined cardiovascular endpoints, major coronary events, and revascularization procedures.

1:08:40supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Ion mobility spectrometry for lipoprotein analysis quantifies lipoprotein subfractions by aerosolizing particles into the air and counting them according to particle size.

"using this technique called ion mobility, which sprays particles into air and then we count them as a function of their size." (said at 1:08:40)

Ion mobility spectrometry (also termed gas-phase electrophoretic mobility molecular analysis or calibrated ion mobility analysis) for lipoprotein characterization operates as described: lipoprotein samples are introduced into the gas phase/aerosolized using electrospray ionization, separated according to particle size via differential mobility, and directly counted across specific size subfractions.

1:15:11supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Cardiovascular and lipid guidelines establish an LDL cholesterol level of 190 mg/dL or greater as a threshold mandating clinical intervention and statin therapy, often driven by underlying genetic conditions such as LDL receptor abnormalities.

"the uh sort of consensus number that the lipid community and cardiology community has accepted as mandating attention uh for genetic reasons is an LDL actually at 190... If your LDL is 190 and greater, the particle measurement probably isn't going to affect the treatment decision because in almost all cases those patients have genetic ApoE—may be part of it, but not not the cause of those very high levels. That's usually an LDL receptor abnormality. Those patients are at sufficiently high lifelong risk of heart disease that they are candidates for statin therapy almost in all cases." (said at 1:15:11)

Major cardiovascular and lipid guidelines, including the AHA/ACC Cholesterol Guidelines, define severe primary hypercholesterolemia as an LDL-C level ≥190 mg/dL. Individuals meeting this threshold are categorized into a distinct statin-benefit group that mandates high-intensity statin therapy for primary prevention of atherosclerotic cardiovascular disease without requiring prior 10-year risk estimation. This severe elevation frequently reflects genetic dyslipidemias, most notably familial hypercholesterolemia caused by pathogenic mutations in the low-density lipoprotein receptor (LDLR) gene, among other lipid regulatory genes.

1:16:15supportedhighDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Triglyceride levels exhibit substantially greater day-to-day variability and measurement instability over time than LDL cholesterol and HDL cholesterol.

"Triglyceride hasn't entered into it because it's so tightly related to everything else. It's a very bouncy measurement. It's much less stable over time, even from day to day, as LDL cholesterol and HDL cholesterol." (said at 1:16:15)

Clinical and laboratory studies evaluating biological variability consistently demonstrate that serum triglycerides have substantially higher within-subject (intra-individual) biological variation over time and from day to day compared to LDL cholesterol and HDL cholesterol. Studies of lipid biological variability report within-subject coefficients of variation (CV_I) for triglycerides around 20–28%, whereas CV_I values for LDL cholesterol and HDL cholesterol are markedly lower, typically ranging from 5–10%.

1:17:20supportedmoderateDr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart D

Adding LDL particle number or subfraction measurements to standard cardiovascular risk formulas (which include age, sex, blood pressure, diabetes, LDL-C, and HDL-C) offers minimal additional statistical risk prediction because the variables are highly interrelated.

"when you have some very strong predictors of heart disease risk—blood pressure, diabetes, even LDL cholesterol, HDL cholesterol, these standard measurements—and you throw them into a risk formula and you add in age and sex, you can explain a lot of risk that way... If you add LDL particles or more refined measurements of particle concentrations into those formulas, you don't get much additional explanation of risk because a lot of these things are interrelated with one another." (said at 1:17:20)

Large prospective cohort analyses demonstrate that adding LDL particle number (LDL-P) or other advanced lipoprotein measures to standard cardiovascular risk prediction formulas (which already incorporate age, sex, blood pressure, diabetes, and standard lipid panel variables) provides minimal to no incremental statistical discrimination (as measured by the C-statistic). While particle measures independently correlate with cardiovascular disease, their predictive associations are substantially attenuated after adjusting for standard lipid panel variables because these biomarkers are closely interrelated.

Fact-checked episodes

Publications